Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group

Mulder RL, Font-Gonzalez A, Hudson MM, van Santen HM, Loeffen EA, Burns KC, Quinn GP, van Dulmen-den Broeder E, Byrne J, Haupt R, Wallace WH, van den Heuvel-Eibrink MM, Anazodo A, Anderson RA, Barnbrock A, Beck JD, Bos AM, Demeestere I, Denzer C, Di Iorgi N, Hoefgen HR, Kebudi R, Lambalk C, Langer T, Meacham LR, Rodriguez-Wallberg K, Stern C, Stutz-Grunder E, van Dorp W, Veening M, Veldkamp S, van der Meulen E, Constine LS, Kenney LB, van de Wetering MD, Kremer LC, Levine J, Tissing WJ, Berger C, Diesch T, Dirksen U, Ginsberg J, Giwercman A, Grabow D, Gracia C, Hunter SE, Inthorn J, Kaatsch P, Kelvin JF, Klosky JL, Laven JS, Lockart BA, Neggers SJ, Paul NW, Peate M, Phillips B, Reed DR, Tinner EME, van den Berg M, Verhaak C (2021)


Publication Type: Journal article, Review article

Publication year: 2021

Journal

Book Volume: 22

Pages Range: e45-e56

Journal Issue: 2

DOI: 10.1016/S1470-2045(20)30594-5

Abstract

Female patients with childhood, adolescent, and young adult cancer are at increased risk for fertility impairment when treatment adversely affects the function of reproductive organs. Patients and their families desire biological children but substantial variations in clinical practice guidelines reduce consistent and timely implementation of effective interventions for fertility preservation across institutions. As part of the PanCareLIFE Consortium, and in collaboration with the International Late Effects of Childhood Cancer Guideline Harmonization Group, we reviewed the current literature and developed a clinical practice guideline for fertility preservation in female patients who were diagnosed with childhood, adolescent, and young adult cancer at age 25 years or younger, including guidance on risk assessment and available methods for fertility preservation. The Grading of Recommendations Assessment, Development and Evaluation methodology was used to grade the available evidence and to form the recommendations. This clinical practice guideline leverages existing evidence and international expertise to develop transparent recommendations that are easy to use to facilitate the care of female patients with childhood, adolescent, and young adult cancer who are at high risk for fertility impairment. A complete review of the existing evidence, including a quality assessment, transparent reporting of the guideline panel's decisions, and achievement of global interdisciplinary consensus, is an important result of this intensive collaboration.

Authors with CRIS profile

Involved external institutions

Boyne Research Institute IE Ireland (IE) Vrije Universiteit Amsterdam (VU) / University Amsterdam NL Netherlands (NL) University of Zurich / Universität Zürich (UZH) CH Switzerland (CH) St. Jude Children’s Research Hospital US United States (USA) (US) University of Rochester Medical Center Rochester, NY US United States (USA) (US) Princess Máxima Center NL Netherlands (NL) Dutch Childhood Cancer Parent Organisation (VOKK) / Vereniging Ouders, Kinderen en Kanker (VOKK) NL Netherlands (NL) Universitätsklinikum Ulm DE Germany (DE) Hôpital Erasme BE Belgium (BE) Sydney Children’s Hospitals Network AU Australia (AU) Karolinska University Hospital / Karolinska Universitetssjukhuset SE Sweden (SE) University of Edinburgh GB United Kingdom (GB) University Medical Centre Utrecht (UMC Utrecht) NL Netherlands (NL) Royal Hospital for Sick Children GB United Kingdom (GB) Washington University US United States (USA) (US) University Medical Center Groningen (UMCG) / Universitair Medisch Centrum Groningen NL Netherlands (NL) Melbourne IVF AU Australia (AU) Universitätsklinikum Schleswig-Holstein (UKSH) DE Germany (DE) University of Genova / Università degli Studi di Genova IT Italy (IT) Weill Cornell Medicine US United States (USA) (US) Cincinnati Children's Hospital Medical Center US United States (USA) (US) Erasmus University Medical Center (MC) NL Netherlands (NL) Istituto Giannina Gaslini IT Italy (IT) Children's Healthcare of Atlanta Inc. US United States (USA) (US) New York University (NYU) US United States (USA) (US) University of Amsterdam NL Netherlands (NL) Veterans Affairs Healthcare System Boston and Harvard Medical School US United States (USA) (US) Universitätsklinikum Frankfurt am Main (KGU) DE Germany (DE) Istanbul University Cerrahpaşa / İstanbul Üniversitesi Cerrahpaşa (IUC) TR Turkey (TR)

How to cite

APA:

Mulder, R.L., Font-Gonzalez, A., Hudson, M.M., van Santen, H.M., Loeffen, E.A., Burns, K.C.,... Verhaak, C. (2021). Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncology, 22(2), e45-e56. https://doi.org/10.1016/S1470-2045(20)30594-5

MLA:

Mulder, Renée L., et al. "Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group." Lancet Oncology 22.2 (2021): e45-e56.

BibTeX: Download